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OBJECTIVE—Previous studies have suggested that preterm birth is associated with diabetes
later in life. These studies have shown inconsistent results for late preterm births and have had
various limitations, including the inability to evaluate diabetic outpatients or to estimate risk
across the full range of gestational ages. Our objective was to determine whether preterm birth is
associated with diabetes medication prescription in a national cohort of young adults.
RESEARCH DESIGN AND METHODS—This was a national cohort study of 630,090
infantsborninSwedenfrom1973through1979(including27,953bornpreterm,gestationalage
,37 weeks), followed for diabetes m e d i c a t i o np r e s c r i p t i o ni n2 0 0 5 –2009 (ages 25.5–37.0
years). Medication data were obtained from all outpatient and inpatient pharmacies throughout
Sweden.
RESULTS—Individuals born preterm, including those born late preterm (gestational age 35–
36 weeks), had modestly increased odds ratios (ORs) for diabetes medication prescription rel-
ative to those born full term, after adjusting for fetal growth and other potential confounders.
Insulin and/or oral diabetes medications were prescribed to 1.5% of individuals born preterm
compared with 1.2% of those born full term (adjusted OR 1.13 [95% CI 1.02–1.26]). Insulin
withoutoraldiabetesmedicationswasprescribedto1.0%ofindividualsbornpretermcompared
with 0.8% of those born full term (1.22 [1.08–1.39]).
CONCLUSIONS—Preterm birth, including late preterm birth, is associated with a modestly
increased risk of diabetes in young Swedish adults. These ﬁndings have important public health
implications given the increasing number of preterm births and the large disease burden of
diabetes, particularly when diagnosed in young adulthood.
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L
ow birth weight may result from
either preterm birth or fetal growth
delay and is associated with diabetes
in later life (1,2). Several studies (3–9),
but not all (10), that have examined the
speciﬁc contributions of preterm birth
and fetal growth have suggested that pre-
term birth is an independent risk factor
for type 2 diabetes in later life. Others
(11,12) have suggested an independent
association between early gestational age
at birth andtype 1diabetes.Thesestudies
have had various limitations, including
the use of self-reported diagnoses (4);
the use of hospital diagnoses, which ex-
cludes the larger number of patients
treatedinoutpatientsettings(7);theinabil-
ity or insufﬁcient power to estimate risk
across the full range of gestational ages
(3,5,6,8,10–12); or have shown inconsis-
tent results for late preterm births (9). In
addition, most of these studies have fo-




To address these gaps in the current
knowledge, we conducted a national co-
hort study using nationwide pharmacy
data to examine whether preterm birth is
associated with increased prescription of
insulin and oral diabetes medications in
young adulthood (ages 25.5–37.0 years).
Diabetes medication data were obtained
from 4.5 years of outpatientand inpatient
pharmacy records from all health care
settings throughout Sweden. Young
adults are of particular interest because
most diabetes in this age range is type 1
diabetes (13), and a diagnosis of diabetes
at this age carries disproportionately high
morbidity and mortality (14). We hy-
pothesized that young adults who were
born preterm have a higher prevalence
of diabetes medication prescription than
those who were born full term.
RESEARCH DESIGN AND
METHODS—We identiﬁed 648,276
individuals in the Swedish Medical Birth
Register who were born from 1973
through 1979. Of this total, we excluded
6,553 (1.0%) individuals who were no
longer living in Sweden at the time of
follow-up (2005–2009), 7,926 (1.2%)
who had signiﬁcant congenital anomalies
(i.e., other than undescended testicle,
preauricular appendage, congenital ne-
vus, or hip dislocation), and 1,882
(0.3%) who had missing information on
birth weight. To remove possible coding
errors,wealso excluded six(,0.01%)in-
dividuals who had a reported gestational
age,23weeksand1,819(0.3%)individ-
uals who had a reported birth weight .4
SDsaboveorbelowthemeanbirthweight
forgestationalageandsexfromaSwedish
reference growth curve (15). A total of
630,090 individuals (97.2% of the origi-
nal cohort) remained for inclusion in the
study.
Study period
Study participants were followed for di-
abetes medication prescriptions from 1
July 2005 through 31 December 2009,
the ﬁrst 4.5 years that the national phar-
macy register was kept. These individuals
were between 25.5 and 37.0 years of age
during the follow-up period.
Outcome measurement
Medication prescription data were ob-
tained using a national pharmacy register
maintained by the Swedish National
BoardofHealthandWelfare.Thisregister
contains a record of each medication
prescribed by a health care provider and
dispensed to a patient by any outpatient or
inpatient pharmacy in Sweden. For inpa-
tients, the register includes all medications
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ORIGINAL ARTICLEprescribed to a patient upon discharge
from the hospital. All medication data are
categorized according to the Anatomical
Therapeutic Chemical (ATC) classiﬁca-
tion system developed by the World
HealthOrganizationCollaboratingCentre
for Drug Statistics Methodology. We ob-
tained all outpatient and inpatient pre-
scriptions for “d r u g su s e di nd i a b e t e s ”
(ATC code A10). These data were linked
to the national Medical Birth Register us-
ing an anonymous identiﬁcation number.
The outcome was deﬁned alternatively as
at least one prescription of any diabetes
medication (A10) or at least one pre-
scription of insulin (A10A) and no pre-
scriptions of oral diabetes medications
(A10B), during the follow-up period.
Exposure measurement
The exposure of interest was gestational
age at birth, which wasbased on maternal
report of last menstrual period and cate-
gorized as 23–28, 29–34, 35–36, 37–42
(fullterm),and$43weeks.Thisinforma-
tion was obtained from prenatal andbirth
records in a national research database,
WomMed, located at the Center for Pri-
maryHealthCareResearch,LundUniver-
sity, Sweden. Cut points were chosen in
order to have adequate numbers in each
category for statistical analysis.
Adjustment variables
The WomMed database also contains
sociodemographic information for the
parents, including age, marital status,
and socioeconomic indicators, collected
annually starting in 1990. For the current
study, sociodemographic characteristics
were obtained using the Swedish Popu-
lation and Housing Census of 1990, the
most recent census when the young
adults in this study (who were then 11–
17 years of age) were still likely to be re-
siding in the same household as their
mothers. This information was used to
identify maternal characteristics that
would reﬂect the social conditions of
these young adults during their upbring-
ing, which may be associated with subse-
quent risk of diabetes. An anonymous,
serial-number version of the personal
identiﬁc a t i o nn u m b e r( s i m i l a rt ot h e
U.S. Social Security number but nearly
100% complete) was used to link the
mothers to their children. The follow-
ing variables were included as potential
confounders.
Age. Modeled as acontinuous variableby
infant’s date of birth.
Sex. Female or male.
Maternal age at delivery. This was in-
cluded because advanced maternal age of
,20,20–24,25–29,30–34,or$35years
is associated with preterm delivery and
with gestational diabetes, which is a risk
factor for the development of diabetes in
the offspring (16).
Maternal marital status in 1990. Married/
cohabiting, never married, divorced, or
widowed.
Maternal education in 1990. Compul-
sory high school or less (#9 years), prac-
tical high school or some theoretical high
school (10–11 years), or theoretical high
school and/or college ($12 years).
Family income in 1990. Calculated as
the annual family income divided by the
number of people in the family or family
income per capita, using a weighted
system whereby small children were
given lower weights than adolescents
and adults. The ﬁnal variable was catego-
rized in quartiles.
Maternal prescription of diabetes
medications. Prescription of diabetes
medications(ATCcodeA10)tothemothers




age and sex was used as a measure of fetal
growth, categorized into six groups ac-
cording to the number of SDs from the
mean birth weight for gestational age and
sex from a Swedish reference growth
curve (,22S D s ,$22S D sa n d,21




Generalized estimating equations were
used to estimate odds ratios (ORs) and
95% CIs for the association between
gestational age at birth (categorized as
23–28, 29–34, 35–36, 37–42, and $43
weeks) and prescription of diabetes med-
ications (as deﬁn e da b o v e )i ny o u n g
adulthood (ages 25.5–37.0 years), using
full-term birth (37–42 weeks) as the refer-
ence category. Analyses were conducted
unadjusted and then were adjusted in
two different models. Adjusted model 1
included the following infant and ma-
ternal characteristics as potential con-
founders: age, sex, maternal age at
delivery, maternal maritalstatus, maternal
education, family income, and maternal
prescription of diabetes medications dur-
ing the follow-up period. Adjusted model
2 included the same set of variables and
fetal growth. Robust SEs were used in all
models in order to account for correlation
among siblings. We also explored ﬁrst-
order interactions between gestational age
at birth and each of the model covariates
with respect to diabetes medication pre-
scriptioninyoungadulthood,usingalike-
lihood ratio test to evaluate for statistical
signiﬁcance. All analyses were conducted
using Stata statistical software, version
11.0 (17).
RESULTS—Of 630,090 individuals
who were identiﬁed, 27,953 (4.4%)
were born prematurely (gestational age
,37 weeks), including 419 (0.1%) born
at 23–28 weeks, 8,509 (1.4%) born at
29–34 weeks, and 19,025 (3.0%) born
at 35–36 weeks. Compared with individ-
uals who were born full term, those who
were born prematurely were more likely
to be male, and their mothers were more
likely to be aged ,20 or $3 5y e a r sa tt h e
time of delivery, to be divorced or never
married, to have the lowest educational
attainment and lowest family incomes,
and/or to be prescribed diabetes medica-
tions during the follow-up period (data
not shown).
A higher prevalence of any diabetes
medicationorofonlyinsulinprescription
was observed among individuals born
preterm (gestational age ,37 weeks), in-
cluding among those born late preterm
(35–3 6w e e k s ) ,c o m p a r e dw i t ht h o s e
born full term (Table 1). A total of 7,751
(1.2%) young adults from the entire co-
hort were prescribed at least one diabetes
medication, including 1.5% ofthoseborn
at 35–36 weeks, 1.4% of those born at
29–34 weeks, and 1.9% of those born at
23–28 weeks’ gestation. A total of 4,997
(0.8%) individuals were prescribed insu-
lin without being prescribed oral diabetes
medications during the study period, in-
cluding 1.0% of those born at either 35–
36 weeks or 29–34 weeks, and 1.2% of
those born at 23–28 weeks’ gestation.
Young adults who were born pre-
term, including those born late preterm
(35–36 weeks’ gestation), had modestly
increased relative odds of diabetes medi-
cation prescription (Table 2). Adjustment
for potential confounders, with or with-
out fetal growth, had only modest effects
on the ORs. In the fully adjusted model,
comparing young adults born preterm
(,37 weeks’ gestation) to those born
full term, the OR for any diabetes medi-
cation prescription was 1.13 (95% CI
1.02–1.26) and for insulin without oral
diabetes medication prescription 1.22
(1.08–1.39). Higher ORs were observed
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Preterm birth and diabetes in young adulthoodfor young adults born extremely preterm
(23–28 weeks’ gestation), but the small
number of these individuals and the low
background prevalence of diabetes in
young adulthood resulted in wider CIs
for these estimates. Modestly increased
ORs were observed for young adults
born at 29–34 weeks and 35–36 weeks’
gestation,andtherewaslittledifferencein
risk estimates across this gestational age
range.
A weak association also was found
between poor fetal growth and diabetes
medication prescription in young adult-
hood.Afteradjustingforgestationalageat
birth and the other potential confounders
included in adjusted model 1, ORs were
1.41(95%CI1.26–1.59)and1.13(1.06–
1.21) for the two smallest fetal growth
categories (,22 SDs and $22S D sa n d
,21 SD, respectively), relative to individ-
uals with fetal growth $0 SDs and ,1S D
fromthereferenceusingastandardSwedish
growthcurve(15).Noﬁrst-orderinterac-
tions were statistically signiﬁcant at the
P , 0.01 level, including no interaction
between gestational age at birth and fetal
growth (P =0 . 3 3 ) .
CONCLUSIONS—These ﬁndings
based on nationwide outpatient and in-
patient medication data show that indi-
viduals who are born prematurely,
including the large numbers who are
born late preterm, have an increased risk
of diabetes in young adulthood. This
association was independent of fetal
growth. Most diabetes in this cohort was
likely type 1 diabetes, as identiﬁed by the
prescription of insulin without any oral
diabetesmedications.Thehighestrelative
oddswereobservedforyoungadultsborn
extremely preterm (23–28 weeks’ gesta-
tion), although the precision of these es-
timates was limited as a result of the
relativelysmallnumberoftheseindividuals
who have now reached young adulthood.
Larger effect sizes and disease burden may
be expected in older populations as in-
creasing numbers of individuals who were
born preterm continue to age.
Themodestlyincreasedriskofdiabetes
in young adulthood that was observed in
this study may have a disproportionately
largepublichealthimpactasaresultofthe
high morbidity and mortality that tend
to follow diabetes when diagnosed at this
age. It is estimated that a diagnosis of di-
abetes at the age of 40 years, for example,
is associated with a loss of 11.6 and 14.3
life-years for men and women,respectively
(14). In addition, most diabetes in young
adulthood is type 1 diabetes, which
incurs a disproportionately high eco-
nomic burden in terms of medical costs
and lost income (18).
The observed association between
late preterm birth (35–36 weeks’ gesta-
tion) and diabetes medications in young
adulthood also has important implica-
tions. The total prevalence of preterm
birth is 12–13% in the U.S., (19) similar
to that in Africa (20) or Brazil (21), com-
p a r e dw i t h4 –9% in Europe (19). Late
preterm births constitute approximately
two-thirds of this total in the current
study and in other populations (19).
Given the large and increasing number
of late preterm births, even a modestly
increasedrisk of diabetesamong these in-
dividuals may have a large public health
impact.
These results are compatible with
most previous smaller studies of preterm
birth and either type 1 or type 2 diabetes.
A study of 72 children aged 4–10 years
reported that those born preterm, regard-
less of whether appropriate or small for
gestational age, had decreased insulin
sensitivity compared with children born
full term and appropriate for gestational
age (3). Another study of 332 adults aged
18–27 years reported that individuals
bornpreterm,regardlessofwhethersmall
or appropriate for gestational age, had in-
creased insulin resistance and glucose
Table 1—Diabetes medication prescription in young adulthood (ages 25.5–37.0 years) by gestational age at birth (1973–1979)
Medications (ATC code)
Gestational age
,37 weeks 23–28 weeks 29–34 weeks 35–36 weeks 37–42 weeks $43 weeks All
n 27,953 419 8,509 19,025 583,571 18,566 630,090
Any diabetes medications (A10) 407 (1.5) 8 (1.9) 117 (1.4) 282 (1.5) 7,103 (1.2) 241 (1.3) 7,751 (1.2)
Any insulin (A10A) without oral
diabetes medications (A10B) 278 (1.0) 5 (1.2) 86 (1.0) 187 (1.0) 4,587 (0.8) 132 (0.7) 4,997 (0.8)
Data are n (%).
Table 2—ORs for association between gestational age at birth (1973–1979) and diabetes
medication prescription in young adulthood (ages 25.5–37.0 years)
Medications (ATC code)
(outcome variable)
Unadjusted Adjusted model 1* Adjusted model 2†
OR (95% CI) OR (95% CI) OR (95% CI)
Any diabetes medications (A10)
Gestational age (predictor variable) (weeks)
,37 1.20 (1.08–1.33) 1.16 (1.04–1.28) 1.13 (1.02–1.26)
23–28 1.56 (0.77–3.18) 1.54 (0.76–3.15) 1.53 (0.75–3.11)
29–34 1.13 (0.93–1.36) 1.09 (0.90–1.32) 1.05 (0.87–1.28)
35–36 1.22 (1.08–1.38) 1.18 (1.04–1.33) 1.16 (1.03–1.31)
37–42 1.00 1.00 1.00
$43 1.07 (0.94–1.21) 1.03 (0.90–1.17) 0.98 (0.86–1.11)
Any insulin (A10A) without oral diabetes medications (A10B)
Gestational age (predictor variable) (weeks)
,37 1.26 (1.12–1.43) 1.24 (1.09–1.40) 1.22 (1.08–1.39)
23–28 1.53 (0.64–3.70) 1.52 (0.63–3.67) 1.51 (0.63–3.65)
29–34 1.28 (1.03–1.61) 1.26 (1.00–1.57) 1.25 (1.00–1.56)
35–36 1.25 (1.08–1.45) 1.22 (1.05–1.42) 1.21 (1.04–1.40)
37–42 1.00 1.00 1.00
$43 0.90 (0.76–1.08) 0.90 (0.75–1.07) 0.90 (0.76–1.08)
*Adjusted for age, sex, maternal age at delivery, maternal marital status, maternal education, family income,
and maternal prescription of diabetes medications during the follow-up period (1 July 2005 through 31
December 2009). †Adjusted for the same variables included in adjusted model 1 and fetal growth.
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Crump and Associatesintolerance compared with those born
full term and appropriate for gestational
age (5). A study of 87 young adults, aver-
ageage22years,conﬁrmedtheseﬁndings
(6), although a study of 305 young adults
aged 18–24 years did not (10). There are
fewer data on the speciﬁc contribution of
gestational age at birth on risk of type 1
diabetes, but two relatively large studies
of individuals aged ,15 years reported an
association between gestational age ,37
weeks (11) or ,39 weeks (12) and type 1
diabetes, after adjusting for birth weight.
The few studies to date of middle-
aged or older adults have consistently
reported an association between preterm
birth and type 2 diabetes. A Danish study
of 4,744 individuals aged 30–60 years re-
ported that preterm birth,independent of
fetal growth, was associated with type 2
diabetes diagnosed by an oral glucose tol-
erance test (8). A Swedish study of 6,425
individuals born from 1925 to 1949 re-
ported that preterm birth was associated
with a diagnosis of diabetes as identiﬁed
from hospital discharge records from
1987 to 2006 (ages 38–81 years) (7). Un-
like our study, diabetes was ascertained
solelyfromhospitaldischargedata,which
did not include the larger number of di-
abetic patients treated in outpatient set-
tings. A U.K. study of 5,792 adults aged
46–50 years reported that preterm birth
was associated with self-report of a physi-
cian’s diagnosis of diabetes after age 20
years (4). A Finnish study of 12,731
adults born between 1934 and 1944 re-
ported that preterm birth at gestational
age ,35 weeks was associated with spe-
cial reimbursement for diabetes medica-
tion after 40 years of age (9). However, in
contrastto the currentstudy, late preterm
birth (35 to ,37 weeks’ gestation) in that
study was associated with a nonsigniﬁ-
cantly lower risk of diabetes medication
reimbursement.
Previous evidence for an association
between low birth weight and insulin
resistance led to the fetal origins hypoth-
esis that fetal undernutrition in middle
and late gestation triggers hormonal and
metabolic changes that lead to lasting in-
sulin resistance and diabetes (22). Experi-
mental (23) and clinical (24) data have
shown that prenatal and/or postnatal die-
tary restriction predisposes individuals to
persistent abnormalities in glucose regula-
tion. Additional research on the effects of
perinatal nutrition and growth patterns on
glucose metabolism and autoimmune re-
sponses is needed to clarify the etiologic
pathways.
One limitation of the current study is
the use of diabetes medication prescrip-
tions as a surrogate measure for diabetes.
This approach fails to identify individuals
who have diabetes but remain undiag-
nosed and those who are not medically
treated. If this occurs nondifferentially
with respect to preterm birth status, it
biases the results toward the null hypoth-
esis,inwhichcasethereportedORsinthe
current study would underestimate the
true effect sizes. We are unable to exclude
the possibility of diagnostic or prescrip-
tion bias among individualsin this cohort
who were born preterm. However, the
prevalence of diabetes medication pre-
scription in this study was similar to
previously published prevalences of di-
abetes in the same age range in Sweden
using World Health Organization diag-
nostic criteria (25), suggesting that the
amount of bias, if any, is small.
Gestational diabetes, maternal weight,
and/or postnatal growth patterns may be
important potential modiﬁers of the effect
of preterm birth on diabetes in later life,
and this information was unavailable for
this cohort. Another limitation is the
estimation of gestational age by maternal
report of last menstrual period rather than
by ultrasound, which was not yet widely
used at the time these study participants
were born (1973–1979). To reduce mis-
classiﬁcation, we excluded individuals
whose birth weight deviated .4S D s
from the mean reference birth weight for
gestational age and sex. Any remaining
misclassiﬁcation is expected to be nondif-
ferential with respect to preterm birth sta-
tusandthereforetobiastheresultstoward
the null hypothesis.
The most important strength of this
study is its ability to examine the associ-
ation between preterm birth and diabetes
in a large national cohort using nation-
wide outpatient as well as inpatient med-
ication data. These data are remarkably
complete because they are obtained from
all outpatient and inpatient pharmacies
from all health care settings throughout
Sweden, thus avoiding bias that may result
either from self-reporting or from the sole
use of hospital-based data. This also was a
very large study, which was essential for
improving statistical power, which would
otherwise be limited because of the low
background prevalence of diabetes in a
young-adult population. Most diabetes
identiﬁedinthiscohortwastype1diabetes,
which has been relatively understudied.
In summary, this national cohort
studyshowsthat preterm birth,including
late preterm birth, is associated with an
increased risk of diabetes in young Swed-
ish adults. These ﬁndings have important
public health implications because of the
high morbidity and mortality associated
with diabetes when diagnosed in young
adulthood. Larger effect sizes and a larger
burden of disease may be expected as
increasing numbers of individuals born
preterm continue to age. Additional re-
search on the effects of perinatal nutrition
and growth patterns on glucose metabo-
lism and autoimmune responses is
needed to elucidate the etiologic mecha-
nisms. Improved recognition of diabetes
and other cardiovascular risk factors
among individuals born preterm is an
urgent priority and may lead to earlier
interventions to prevent disease.
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